View ValuationSynthaverse 将来の成長Future 基準チェック /06現在、 Synthaverseの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Biotechs 収益成長22.9%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Aug 26Synthaverse S.A. to Report First Half, 2025 Results on Sep 30, 2025Synthaverse S.A. announced that they will report first half, 2025 results on Sep 30, 2025Reported Earnings • Sep 26Second quarter 2024 earnings released: EPS: zł0.011 (vs zł0.037 in 2Q 2023)Second quarter 2024 results: EPS: zł0.011 (down from zł0.037 in 2Q 2023). Revenue: zł15.2m (down 17% from 2Q 2023). Net income: zł1.42m (down 45% from 2Q 2023). Profit margin: 9.3% (down from 14% in 2Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has fallen by 21% per year, which means it is performing significantly worse than earnings.お知らせ • May 31Synthaverse S.A., Annual General Meeting, Jun 25, 2024Synthaverse S.A., Annual General Meeting, Jun 25, 2024.Reported Earnings • May 23First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: zł13.9m (up 16% from 1Q 2023). Net loss: zł394.0k (down 153% from profit in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Apr 22Investor sentiment improves as stock rises 31%After last week's 31% share price gain to €1.26, the stock trades at a trailing P/E ratio of 74.3x. Average trailing P/E is 32x in the Biotechs industry in Europe. Total loss to shareholders of 48% over the past three years.Reported Earnings • Apr 11Full year 2023 earnings released: EPS: zł0.07 (vs zł0.093 in FY 2022)Full year 2023 results: EPS: zł0.07 (down from zł0.093 in FY 2022). Revenue: zł58.6m (up 16% from FY 2022). Net income: zł4.76m (down 22% from FY 2022). Profit margin: 8.1% (down from 12% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings.New Risk • Feb 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (10% average weekly change). High level of non-cash earnings (85% accrual ratio). Minor Risks Profit margins are more than 30% lower than last year (6.6% net profit margin). Shareholders have been diluted in the past year (8.1% increase in shares outstanding). Market cap is less than US$100m (€67.6m market cap, or US$72.9m).お知らせ • Feb 02+ 3 more updatesSynthaverse S.A. to Report Q3, 2024 Results on Nov 20, 2024Synthaverse S.A. announced that they will report Q3, 2024 results on Nov 20, 2024Reported Earnings • Nov 25Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: zł8.10m (down 40% from 3Q 2022). Net loss: zł2.42m (down 257% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.Reported Earnings • Sep 21Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: zł18.4m (up 31% from 2Q 2022). Net income: zł2.57m (down 6.1% from 2Q 2022). Profit margin: 14% (down from 20% in 2Q 2022). The decrease in margin was driven by higher expenses.New Risk • Aug 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (64% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Shareholders have been diluted in the past year (7.7% increase in shares outstanding). Market cap is less than US$100m (€85.8m market cap, or US$93.9m).お知らせ • May 27BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A., Annual General Meeting, Jun 22, 2023BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A., Annual General Meeting, Jun 22, 2023, at 11:00 Central European Standard Time.Reported Earnings • Apr 21Full year 2022 earnings releasedFull year 2022 results: Revenue: zł50.4m (up 22% from FY 2021). Net income: zł6.08m (up 43% from FY 2021). Profit margin: 12% (up from 10% in FY 2021). The increase in margin was driven by higher revenue.Valuation Update With 7 Day Price Move • Apr 05Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €1.22, the stock trades at a trailing P/E ratio of 58.6x. Average trailing P/E is 29x in the Biotechs industry in Europe. Total returns to shareholders of 68% over the past year.お知らせ • Feb 03+ 3 more updatesBIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. to Report Q3, 2023 Results on Nov 22, 2023BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. announced that they will report Q3, 2023 results on Nov 22, 2023Valuation Update With 7 Day Price Move • Dec 02Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to €1.17, the stock trades at a trailing P/E ratio of 56.6x. Average trailing P/E is 27x in the Biotechs industry in Europe. Total returns to shareholders of 7.5% over the past year.お知らせ • Dec 02BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. has completed a Follow-on Equity Offering in the amount of PLN 26.5 million.BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. has completed a Follow-on Equity Offering in the amount of PLN 26.5 million. Security Name: Shares Security Type: Common Stock Securities Offered: 5,000,000 Price\Range: PLN 5.3Reported Earnings • Nov 09Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: zł13.4m (up 105% from 3Q 2021). Net income: zł1.54m (up zł2.11m from 3Q 2021). Profit margin: 11% (up from net loss in 3Q 2021). The move to profitability was driven by higher revenue.Reported Earnings • Sep 10Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: zł14.0m (down 3.1% from 2Q 2021). Net income: zł2.73m (down 7.6% from 2Q 2021). Profit margin: 20% (in line with 2Q 2021).Valuation Update With 7 Day Price Move • Jul 22Investor sentiment improved over the past weekAfter last week's 73% share price gain to €1.17, the stock trades at a trailing P/E ratio of 73.9x. Average trailing P/E is 36x in the Biotechs industry in Europe. Total loss to shareholders of 40% over the past year.お知らせ • Jun 07BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A., Annual General Meeting, Jun 29, 2022BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A., Annual General Meeting, Jun 29, 2022, at 11:00 Central European Standard Time.Reported Earnings • May 29First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: zł8.62m (up 55% from 1Q 2021). Net loss: zł758.0k (loss narrowed 36% from 1Q 2021).Reported Earnings • Apr 17Full year 2021 earnings released: EPS: zł0.067 (vs zł0.071 in FY 2020)Full year 2021 results: EPS: zł0.067 (down from zł0.071 in FY 2020). Revenue: zł41.2m (up 2.5% from FY 2020). Net income: zł4.25m (down 4.3% from FY 2020). Profit margin: 10% (in line with FY 2020).お知らせ • Feb 02+ 3 more updatesBIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. to Report Q3, 2022 Results on Nov 09, 2022BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. announced that they will report Q3, 2022 results on Nov 09, 2022Valuation Update With 7 Day Price Move • Dec 01Investor sentiment deteriorated over the past weekAfter last week's 25% share price decline to €1.10, the stock trades at a trailing P/E ratio of 66.5x. Average trailing P/E is 25x in the Biotechs industry in Europe. Total loss to shareholders of 58% over the past year.Reported Earnings • Nov 11Third quarter 2021 earnings releasedThe company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: zł6.55m (down 21% from 3Q 2020). Net loss: zł577.0k (down zł671.0k from profit in 3Q 2020).Reported Earnings • Sep 06Second quarter 2021 earnings released: EPS zł0.047 (vs zł0.007 loss in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: zł14.5m (up 56% from 2Q 2020). Net income: zł2.96m (up zł3.38m from 2Q 2020). Profit margin: 20% (up from net loss in 2Q 2020). The move to profitability was driven by higher revenue.お知らせ • May 05BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. announced that it expects to receive PLN 21.390059 million in funding from Ipopema Securities S.A., Investment ArmBIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (WSE:BML) announced a private placement of 1,734,798 common shares at a price of PLN 12.33 per share for gross proceeds of PLN 21,390,059.34 on May 4, 2021. The transaction will include participation from Ipopema Securities S.A., Investment Arm.お知らせ • Feb 03+ 3 more updatesBIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. to Report Q3, 2021 Results on Nov 09, 2021BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. announced that they will report Q3, 2021 results on Nov 09, 2021Reported Earnings • Nov 13Third quarter 2020 earnings released: EPS zł0.001The company reported a soft third quarter result with weaker earnings and profit margins, although revenues were improved. Third quarter 2020 results: Revenue: zł8.33m (up 4.3% from 3Q 2019). Net income: zł94.0k (down 73% from 3Q 2019). Profit margin: 1.1% (down from 4.4% in 3Q 2019). The decrease in margin was driven by higher expenses. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Synthaverse は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測DB:6NQ - アナリストの将来予測と過去の財務データ ( )PLN Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/202542-20-1612N/A9/30/2024634-5815N/A6/30/2024572-1026N/A3/31/2024614-1181N/A12/31/2023595-118-5N/A9/30/2023533-97-6N/A6/30/2023587-68-2N/A3/31/2023547-432N/A12/31/2022506-343N/A9/30/2022517-300N/A6/30/2022444-26-6N/A3/31/2022445-19-4N/A12/31/2021414-22-3N/A9/30/2021395-111N/A6/30/2021405-14N/A3/31/2021352-40N/A12/31/2020404-20N/A9/30/2020412-4-2N/A6/30/202040334N/A3/31/202040345N/A12/31/201939278N/A9/30/201935-29N/A10N/A6/30/201936-31N/A3N/A3/31/201935-32N/A7N/A12/31/201832-32N/A-1N/A9/30/20183110N/A-5N/A6/30/20183111N/A-2N/A3/31/2018301N/A-2N/A12/31/2017311N/A4N/A9/30/201731-23N/A31N/A6/30/201732-27N/A30N/A3/31/201737-26N/A10N/A12/31/201636-26N/A16N/A9/30/201646-48N/A-4N/A6/30/201645-45N/A-15N/A3/31/201647-35N/A5N/A12/31/201543-37N/A-3N/A9/30/201538-2N/A-5N/A6/30/201536-2N/A2N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 6NQの予測収益成長が 貯蓄率 ( 1.9% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: 6NQの収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: 6NQの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: 6NQの収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 6NQの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 6NQの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 18:32終値2026/05/22 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Synthaverse S.A. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Aug 26Synthaverse S.A. to Report First Half, 2025 Results on Sep 30, 2025Synthaverse S.A. announced that they will report first half, 2025 results on Sep 30, 2025
Reported Earnings • Sep 26Second quarter 2024 earnings released: EPS: zł0.011 (vs zł0.037 in 2Q 2023)Second quarter 2024 results: EPS: zł0.011 (down from zł0.037 in 2Q 2023). Revenue: zł15.2m (down 17% from 2Q 2023). Net income: zł1.42m (down 45% from 2Q 2023). Profit margin: 9.3% (down from 14% in 2Q 2023). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has fallen by 21% per year, which means it is performing significantly worse than earnings.
お知らせ • May 31Synthaverse S.A., Annual General Meeting, Jun 25, 2024Synthaverse S.A., Annual General Meeting, Jun 25, 2024.
Reported Earnings • May 23First quarter 2024 earnings releasedFirst quarter 2024 results: Revenue: zł13.9m (up 16% from 1Q 2023). Net loss: zł394.0k (down 153% from profit in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Apr 22Investor sentiment improves as stock rises 31%After last week's 31% share price gain to €1.26, the stock trades at a trailing P/E ratio of 74.3x. Average trailing P/E is 32x in the Biotechs industry in Europe. Total loss to shareholders of 48% over the past three years.
Reported Earnings • Apr 11Full year 2023 earnings released: EPS: zł0.07 (vs zł0.093 in FY 2022)Full year 2023 results: EPS: zł0.07 (down from zł0.093 in FY 2022). Revenue: zł58.6m (up 16% from FY 2022). Net income: zł4.76m (down 22% from FY 2022). Profit margin: 8.1% (down from 12% in FY 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 30% per year, which means it is significantly lagging earnings.
New Risk • Feb 10New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (10% average weekly change). High level of non-cash earnings (85% accrual ratio). Minor Risks Profit margins are more than 30% lower than last year (6.6% net profit margin). Shareholders have been diluted in the past year (8.1% increase in shares outstanding). Market cap is less than US$100m (€67.6m market cap, or US$72.9m).
お知らせ • Feb 02+ 3 more updatesSynthaverse S.A. to Report Q3, 2024 Results on Nov 20, 2024Synthaverse S.A. announced that they will report Q3, 2024 results on Nov 20, 2024
Reported Earnings • Nov 25Third quarter 2023 earnings releasedThird quarter 2023 results: Revenue: zł8.10m (down 40% from 3Q 2022). Net loss: zł2.42m (down 257% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
Reported Earnings • Sep 21Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: zł18.4m (up 31% from 2Q 2022). Net income: zł2.57m (down 6.1% from 2Q 2022). Profit margin: 14% (down from 20% in 2Q 2022). The decrease in margin was driven by higher expenses.
New Risk • Aug 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.9% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk High level of non-cash earnings (64% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (6.9% average weekly change). Shareholders have been diluted in the past year (7.7% increase in shares outstanding). Market cap is less than US$100m (€85.8m market cap, or US$93.9m).
お知らせ • May 27BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A., Annual General Meeting, Jun 22, 2023BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A., Annual General Meeting, Jun 22, 2023, at 11:00 Central European Standard Time.
Reported Earnings • Apr 21Full year 2022 earnings releasedFull year 2022 results: Revenue: zł50.4m (up 22% from FY 2021). Net income: zł6.08m (up 43% from FY 2021). Profit margin: 12% (up from 10% in FY 2021). The increase in margin was driven by higher revenue.
Valuation Update With 7 Day Price Move • Apr 05Investor sentiment improves as stock rises 16%After last week's 16% share price gain to €1.22, the stock trades at a trailing P/E ratio of 58.6x. Average trailing P/E is 29x in the Biotechs industry in Europe. Total returns to shareholders of 68% over the past year.
お知らせ • Feb 03+ 3 more updatesBIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. to Report Q3, 2023 Results on Nov 22, 2023BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. announced that they will report Q3, 2023 results on Nov 22, 2023
Valuation Update With 7 Day Price Move • Dec 02Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to €1.17, the stock trades at a trailing P/E ratio of 56.6x. Average trailing P/E is 27x in the Biotechs industry in Europe. Total returns to shareholders of 7.5% over the past year.
お知らせ • Dec 02BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. has completed a Follow-on Equity Offering in the amount of PLN 26.5 million.BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. has completed a Follow-on Equity Offering in the amount of PLN 26.5 million. Security Name: Shares Security Type: Common Stock Securities Offered: 5,000,000 Price\Range: PLN 5.3
Reported Earnings • Nov 09Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: zł13.4m (up 105% from 3Q 2021). Net income: zł1.54m (up zł2.11m from 3Q 2021). Profit margin: 11% (up from net loss in 3Q 2021). The move to profitability was driven by higher revenue.
Reported Earnings • Sep 10Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: zł14.0m (down 3.1% from 2Q 2021). Net income: zł2.73m (down 7.6% from 2Q 2021). Profit margin: 20% (in line with 2Q 2021).
Valuation Update With 7 Day Price Move • Jul 22Investor sentiment improved over the past weekAfter last week's 73% share price gain to €1.17, the stock trades at a trailing P/E ratio of 73.9x. Average trailing P/E is 36x in the Biotechs industry in Europe. Total loss to shareholders of 40% over the past year.
お知らせ • Jun 07BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A., Annual General Meeting, Jun 29, 2022BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A., Annual General Meeting, Jun 29, 2022, at 11:00 Central European Standard Time.
Reported Earnings • May 29First quarter 2022 earnings releasedFirst quarter 2022 results: Revenue: zł8.62m (up 55% from 1Q 2021). Net loss: zł758.0k (loss narrowed 36% from 1Q 2021).
Reported Earnings • Apr 17Full year 2021 earnings released: EPS: zł0.067 (vs zł0.071 in FY 2020)Full year 2021 results: EPS: zł0.067 (down from zł0.071 in FY 2020). Revenue: zł41.2m (up 2.5% from FY 2020). Net income: zł4.25m (down 4.3% from FY 2020). Profit margin: 10% (in line with FY 2020).
お知らせ • Feb 02+ 3 more updatesBIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. to Report Q3, 2022 Results on Nov 09, 2022BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. announced that they will report Q3, 2022 results on Nov 09, 2022
Valuation Update With 7 Day Price Move • Dec 01Investor sentiment deteriorated over the past weekAfter last week's 25% share price decline to €1.10, the stock trades at a trailing P/E ratio of 66.5x. Average trailing P/E is 25x in the Biotechs industry in Europe. Total loss to shareholders of 58% over the past year.
Reported Earnings • Nov 11Third quarter 2021 earnings releasedThe company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: zł6.55m (down 21% from 3Q 2020). Net loss: zł577.0k (down zł671.0k from profit in 3Q 2020).
Reported Earnings • Sep 06Second quarter 2021 earnings released: EPS zł0.047 (vs zł0.007 loss in 2Q 2020)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: zł14.5m (up 56% from 2Q 2020). Net income: zł2.96m (up zł3.38m from 2Q 2020). Profit margin: 20% (up from net loss in 2Q 2020). The move to profitability was driven by higher revenue.
お知らせ • May 05BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. announced that it expects to receive PLN 21.390059 million in funding from Ipopema Securities S.A., Investment ArmBIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. (WSE:BML) announced a private placement of 1,734,798 common shares at a price of PLN 12.33 per share for gross proceeds of PLN 21,390,059.34 on May 4, 2021. The transaction will include participation from Ipopema Securities S.A., Investment Arm.
お知らせ • Feb 03+ 3 more updatesBIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. to Report Q3, 2021 Results on Nov 09, 2021BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. announced that they will report Q3, 2021 results on Nov 09, 2021
Reported Earnings • Nov 13Third quarter 2020 earnings released: EPS zł0.001The company reported a soft third quarter result with weaker earnings and profit margins, although revenues were improved. Third quarter 2020 results: Revenue: zł8.33m (up 4.3% from 3Q 2019). Net income: zł94.0k (down 73% from 3Q 2019). Profit margin: 1.1% (down from 4.4% in 3Q 2019). The decrease in margin was driven by higher expenses.